RxDoctor Payments Data

Benjamin Krasin, MD

Internal Medicine · Kellogg, IDNPI 1316327927

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Johnson & Johnson at 46.0% of the total. Reporting peaked in 2021 at $285 and has fallen 74.8% since, to $72 in 2024.

$1,003in general payments, 2019–2025

Across 64 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$461
  • AstraZeneca$103
  • E.r. Squibb & Sons, L.L.C.$101
  • Merck$91
  • AbbVie$87
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$53
  • plus $107 from 3 others

What the payments were for

  • Food & beverage$1,003100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,003 in reported general payments places this provider in the 85th percentile of 289 internal medicine providers in Idaho.

See all internal medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$133,647
Medicare patients
418
Services billed
1,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$8,609
Cefpodoxime Proxetil18$553
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$441
Cefdinir21$215
ClopidogrelClopidogrel Bisulfate20$127
Prednisone43$124
Doxycycline Hyclate12$111
Metoprolol Succinate14$93
Atorvastatin Calcium18$76
Ciprofloxacin Hcl12$62
Furosemide15$39
Metoprolol Tartrate12$26
Lisinopril11$17
Azithromycin11$15

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$8,60917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 289 internal medicine providers in Idaho.

Other internal medicine in Kellogg

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →